Emerging trends in drugs, addictions, and health最新文献

{"title":"Leberagin C from Macrovipera lebetina Venom: A Potential Therapeutic Agent for Aggressive Cancer","authors":"K. Guizani","doi":"10.1016/j.etdah.2025.100227","DOIUrl":"10.1016/j.etdah.2025.100227","url":null,"abstract":"<div><h3>Introduction</h3><div>Aggressive cancers, such as Inflammatory Breast Cancer (IBC), Glioblastoma (GBM), and Colorectal Cancer (CRC), pose significant treatment challenges due to their rapid progression and high metastatic potential. Current therapies often cause severe side effects, highlighting the need for novel therapeutic strategies. The venom of the Tunisian viper, Macrovipera lebetina, has emerged as a promising source of bioactive molecules with potential anti-cancer properties. This study aimed to isolate and evaluate the anti-tumor effects of Leberagin C, a novel protein derived from M. lebetina venom.</div></div><div><h3>Methods</h3><div>A bio-guided purification approach was employed to isolate Leberagin C from M. lebetina venom. Its pharmacological effects were evaluated using three cancer cell lines: U251 (glioblastoma), Caco-2 (colorectal cancer), and SUM 149 (inflammatory breast cancer). Functional assays assessed the impact of Leberagin C on cell migration, adhesion, and proliferation.</div></div><div><h3>Results</h3><div>Leberagin C demonstrated significant anti-tumor activity in all tested cell lines. It effectively inhibited cancer cell migration, adhesion, and proliferation, suggesting its potential role in disrupting tumor progression.</div></div><div><h3>Conclusions</h3><div>Leberagin C holds promise as a potential therapeutic agent for aggressive cancers, either as a standalone treatment or in combination with existing therapies. Further studies are needed to explore its mechanism of action and clinical applications.</div></div>","PeriodicalId":72899,"journal":{"name":"Emerging trends in drugs, addictions, and health","volume":"5 ","pages":"Article 100227"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145789561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Presentation of Synthetic Cannabinoid Use: A Case Series from a Middle Eastern Rehabilitation Facility","authors":"R.M. Kamal,&nbsp;V. Mohamed-Ali,&nbsp;J. Toufiq,&nbsp;K. Al Kuwari,&nbsp;M.G. Al-Maadheed","doi":"10.1016/j.etdah.2025.100232","DOIUrl":"10.1016/j.etdah.2025.100232","url":null,"abstract":"<div><h3>Introduction</h3><div>Synthetic cannabinoids (SCs), a class of novel psychoactive substances (NPS), are potent cannabinoid receptor agonists that differ significantly from delta-9 tetrahydrocannabinol (THC), often causing unpredictable and serious health effects. This study aimed to assess the presence and clinical impact of SCs among patients admitted to Naufar, Qatar.</div></div><div><h3>Methods</h3><div>A retrospective review of patients medical, psychiatric, and toxicological records in March–April 2024.</div></div><div><h3>Results</h3><div>Included 13 patients (mean age: 32 years) with mainly methamphetamine and opioids as primary substances of abuse. Psychiatric comorbidities were particularly anxiety disorders (69%), and all patients received SSRI prescriptions. Despite negative point-of-care urine screens, confirmatory forensic testing detected NPS/SCs including 5F-ADB, 5F-MDMB-PINACA, m-CPP, and DFMDA. Patients exhibited avoidant behavior, therapy disengagement. Clinically, cognitive dulling, paranoid thoughts, mood instability, restricted affect and sleep disruption were observed. Reported day fatigue, red eyes, nausea, vomiting, and dyspepsia and sore throat were initially misattributed to viral illness. Severe cravings were severe post-withdrawal. Notably, agitation, commonly reported internationally, was absent—possibly due to lower used doses or SSRI influence.</div></div><div><h3>Conclusions</h3><div>Findings confirm the emerging NPS use clinical dangerous, undetectable by routine screening, and highlight the need for enhanced toxicological diagnostics and clinical training in addiction care settings across the GCC.</div></div>","PeriodicalId":72899,"journal":{"name":"Emerging trends in drugs, addictions, and health","volume":"5 ","pages":"Article 100232"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145789565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Achiral LC-MS/MS and Chiral SFC-MS Methods for Quantification of Methoxphenidine and O-Desmethyl-Methoxphenidine Metabolite in Rat Serum and Brain","authors":"M. Kuchar","doi":"10.1016/j.etdah.2025.100234","DOIUrl":"10.1016/j.etdah.2025.100234","url":null,"abstract":"<div><h3>Introduction</h3><div>Methoxphenidine (MXP) is a dissociative anaesthetic increasingly used recreationally and associated with toxicity. However, data on its metabolism, especially in terms of enantiomer-specific distribution, remain limited. This study aimed to develop and validate analytical methods for the quantification of MXP and its primary metabolite, O-desmethyl-methoxphenidine (dmMXP), in rat serum and brain tissue.</div></div><div><h3>Methods</h3><div>Two analytical techniques were developed: an achiral LC-MS/MS method for quantifying racemic MXP and dmMXP, and a chiral SFC-MS method for analyzing individual MXP enantiomers. Serum was prepared by protein precipitation using 0.1% formic acid in acetonitrile, while brain tissue was processed via SALLE. Both methods were validated according to EMA guidelines.</div></div><div><h3>Results</h3><div>The LC-MS/MS method achieved LOQ of 1.00 ng/mL (serum) and 6.00 ng/g (brain) for MXP, and 1.00 ng/mL and 1.50 ng/g for dmMXP. The SFC-MS method quantified MXP enantiomers down to 12.5 ng/mL (serum) and 30.0 ng/g (brain). Pharmacokinetic profiling showed that MXP peaked in serum at 1600 ng/mL (0.5 h) and declined to 5.87 ng/mL at 24 h. In brain tissue, it peaked at 13200 ng/g (0.5 h) and decreased to 36.1 ng/g. dmMXP peaked at 11.8 ng/mL in serum (1 h) and 67.1 ng/g in brain (1 h). Notably, (S)-MXP concentrations in the brain were higher than those of (R)-MXP.</div></div><div><h3>Conclusions</h3><div>The validated LC-MS/MS and SFC-MS methods enable precise quantification of MXP and its metabolite in biological matrices. These tools facilitate pharmacokinetic and toxicological studies, offering insights into the distribution and metabolism of MXP in clinical and forensic contexts.</div></div>","PeriodicalId":72899,"journal":{"name":"Emerging trends in drugs, addictions, and health","volume":"5 ","pages":"Article 100234"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145789568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing under pressure: risk profile of IPED users","authors":"J. Burkauskas,&nbsp;A. Stanyte,&nbsp;L. Lazuras,&nbsp;A. Pranckeviciene,&nbsp;A.R. Dores,&nbsp;I.P. Carvalho,&nbsp;T. Zandonai,&nbsp;P. Simonato,&nbsp;I. De Luca,&nbsp;A. Carollo,&nbsp;K.E. Ábel,&nbsp;A. Szabo,&nbsp;H. Fujiwara,&nbsp;M. Shibata,&nbsp;A. Girleanu,&nbsp;A.R. Melero Ventola,&nbsp;R.M. Santos-Labrador,&nbsp;N.A. Cunha,&nbsp;F. Castro,&nbsp;G. Esposito,&nbsp;O. Corazza","doi":"10.1016/j.etdah.2025.100202","DOIUrl":"10.1016/j.etdah.2025.100202","url":null,"abstract":"<div><h3>Introduction</h3><div>Image- and performance-enhancing drugs (IPEDs) include a wide range of substances used to alter physical performance or appearance. They are a growing public health concern linked to body-image disturbances and maladaptive exercise behaviours. The present study examined the role of exercise addiction, appearance anxiety, and self-compassion in predicting IPED use in a cross-cultural sample of individuals engaged in sports, both professional and non-professional.</div></div><div><h3>Methods</h3><div>This cross-sectional study, based on an online questionnaire and volunteer participation, is part of the Keep Fit 3 survey conducted in nine countries (UK, Spain, Lithuania, Hungary, Japan, Italy, Portugal, Singapore, and Mexico) between May 2023 and June 2024. The survey included the Exercise Addiction Inventory, the Appearance Anxiety Inventory, and the Self-Compassion Scale. Based on IPED use, individuals were classified as non-users, non-harmful users, or potentially risky users. Multinomial logistic regression was used to examine associations between IPED use and potential predictors.</div></div><div><h3>Results</h3><div>Of the 3,514 participants, 71.7% (n = 2,521) reported not using any supplements, 8.1% (n = 286) reported using non-harmful IPEDs, and 20.1% (n = 707) reported using potentially risky IPEDs. We found that non-harmful and potentially risky IPED use were associated with age, sex, appearance anxiety, and exercise addiction in the overall sample and among non-professional athletes, whereas only potentially risky IPED use was related to sex, appearance anxiety, and exercise addiction among professional athletes.</div></div><div><h3>Conclusions</h3><div>Our results highlight risk factors associated with IPED use and the specific characteristics of use among professional athlete populations. Clinicians, trainers, and mental health professionals should be more aware of the risks associated with IPED consumption and possible related psychopathologies and dysfunctional behaviours.</div></div>","PeriodicalId":72899,"journal":{"name":"Emerging trends in drugs, addictions, and health","volume":"5 ","pages":"Article 100202"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145789573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psilocybin and Neuroplasticity: Mechanisms, Therapeutic Potential, and Future Directions","authors":"S. Fereydouni","doi":"10.1016/j.etdah.2025.100215","DOIUrl":"10.1016/j.etdah.2025.100215","url":null,"abstract":"<div><h3>Introduction</h3><div>Mental health disorders, including depression, anxiety, and post-traumatic stress disorder (PTSD), remain a significant global health concern, requiring novel therapeutic approaches. Psilocybin, a psychedelic compound found in certain mushrooms, has shown potential in modulating neuroplasticity, a critical process for cognitive flexibility and mental well-being. This review explores psilocybin’s role in enhancing neuroplasticity and its therapeutic implications for mental disorders.</div></div><div><h3>Methods</h3><div>A comprehensive literature review was conducted (2015–2024) using PubMed, PsycINFO, and other databases. Search terms included “Mental Health,” “Psilocybin,” “Neuroplasticity,” and “Mental Disorders.” Studies on psilocybin’s effects on neuroplasticity in human and animal models were included. Extracted data were synthesized chronologically to identify key findings and trends.</div></div><div><h3>Results</h3><div>Psilocybin acts primarily via 5-HT2A receptor activation, increasing synaptic connectivity, dendritogenesis, and neurogenesis. It enhances neuroplasticity through the BDNF-TrkB signaling pathway, contributing to antidepressant and pro-social effects. Clinical and preclinical evidence supports improvements in mood regulation, fear extinction, and cognitive function. Some inconsistencies in neuroplastic outcomes highlight the need for standardized protocols and further investigation.</div></div><div><h3>Conclusions</h3><div>Psilocybin-induced neuroplasticity is a promising avenue for treating neuropsychiatric disorders. Further research is needed to clarify long-term effects, optimal dosing, and molecular mechanisms to ensure safe and effective clinical applications.</div></div>","PeriodicalId":72899,"journal":{"name":"Emerging trends in drugs, addictions, and health","volume":"5 ","pages":"Article 100215"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145789648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Relative Impact of UK and Chinese Drug Controls on NPS Detections in Deaths in England, Wales and Northern Ireland","authors":"C. Copeland","doi":"10.1016/j.etdah.2025.100208","DOIUrl":"10.1016/j.etdah.2025.100208","url":null,"abstract":"<div><h3>Introduction</h3><div>Novel psychoactive substances (NPS) are typically controlled as evidence of their harms emerge. While individual countries implement their own drug controls, broader restrictions can be introduced by the United Nations (UN). This study assessed the impact of UK, Chinese and UN controls on NPS availability in the UK.</div></div><div><h3>Methods</h3><div>Deaths occurring 2007-2022 were extracted from the National Programme on Substance Use Mortality and analysed.</div></div><div><h3>Results</h3><div>Analysis focussed on opioids, stimulants and cannabinoids – the main drug classes targeted by recent Chinese and UN controls. Among 1,669 NPS detections, 254 were NPS opioids, 927 NPS stimulants, 488 NPS cannabinoids. Of the 115 distinct NPS identified, 87.8% (n=101) were first controlled in the UK. However, marked reductions in NPS detections only occurred following the introduction of Chinese controls. For example, following the synthetic cannabinoid receptor agonists (SCRAs) generic ban in the UK under the Psychoactive Substances Act (2016), SCRA detections continued to increase (2016 n=19, 2017 n=69) whereas a significant drop was observed upon their generic control in China in 2021 (2021 n=112, 2022 n=14).</div></div><div><h3>Conclusions</h3><div>Despite earlier UK controls, reductions in NPS availability in the UK were primarily associated with later Chinese restrictions, suggesting that international supplier controls may be more effective than domestic legislation.</div></div>","PeriodicalId":72899,"journal":{"name":"Emerging trends in drugs, addictions, and health","volume":"5 ","pages":"Article 100208"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145789803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amanita Muscaria and Pantherina – Benefit or Danger? Danger Isoxazole Containing Amanita, Present Situation and Prospects for the Legality of It in Europe","authors":"E. Alexandrova,&nbsp;M. Vishnevskii","doi":"10.1016/j.etdah.2025.100191","DOIUrl":"10.1016/j.etdah.2025.100191","url":null,"abstract":"<div><h3>Introduction</h3><div>The popularity of the red fly agaric in the past 10 years has led not only to a positive impact on the inhabitants of Europe and Asia, but also to a number of hospitalizations and even deaths. Independent macrodosing and combination with other entheogens is especially dangerous.</div></div><div><h3>Methods</h3><div>Based on the available literature, as well as independent field studies on volunteers, as well as police and hospitals data.</div></div><div><h3>Results</h3><div>Tables of the most dangerous combinations of Red and Panther fly agaric with other plant and chemical entheogens were compiled. A graph of the frequency of hospitalization of patients with poisoning with substances of red and panther fly agaric for 2023-2025 is presented. A list of side effects of red and panther fly agaric during microdosing has been compiled.</div></div><div><h3>Conclusions</h3><div>Despite the enormous benefits of red and panther fly agarics in the treatment of somatic and mental diseases, the uncontrolled use of fly agaric macrodoses, and especially their combination with various other entheogens, can lead to a dangerous outcome.</div></div>","PeriodicalId":72899,"journal":{"name":"Emerging trends in drugs, addictions, and health","volume":"5 ","pages":"Article 100191"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145789980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Cognitive Pharmacodynamics Following Dose Escalations with 3-Methylmethcathinone (3-MMC): A First in Human, Designer Drug Study","authors":"J. Reckweg,&nbsp;J. Ramaekers,&nbsp;N. Mason,&nbsp;K. Kuypers,&nbsp;S. Toennes,&nbsp;E. Theunissen","doi":"10.1016/j.etdah.2025.100251","DOIUrl":"10.1016/j.etdah.2025.100251","url":null,"abstract":"<div><h3>Introduction</h3><div>3-Methylmethcathinone (3-MMC) is a designer drug belonging to the group of synthetic cathinones. The compound has been scheduled in many jurisdictions because of public health concerns associated with excessive use. To date, there are no clinical studies that have evaluated the risk profile of 3-MMC in the recreational range of low to moderate doses.</div></div><div><h3>Methods</h3><div>This first-in-human study (N = 14) assessed the impact of three escalating doses of 3-MMC (25, 50 and 100 mg) on vital signs, neurocognitive function, state of consciousness, appetite and drug desire, in a cross-over, placebo-controlled trial. Neurocognitive tests and questionnaires as well as measures of vital signs were repeatedly administered up to 5 h after dosing.</div></div><div><h3>Results</h3><div>3-MMC caused dose-dependent increases in heart rate and blood pressure, though not of clinical significance, and feelings of subjective high. 3-MMC induced dose-related enhancement of task performance across several neurocognitive domains, including processing speed, cognitive flexibility, psychomotor function, attention and memory. Impulse control was not affected by 3-MMC. Participants also reported mild increases in dissociative and psychedelic effects, decreased appetite, and gave greater ratings of liking and wanting for 3-MMC that were transient over time.</div></div><div><h3>Conclusions</h3><div>The cardiovascular, psychostimulant and psychotomimetic profile of 3-MMC appears consistent with that of compounds structurally related to amphetamine. It is concluded that low to moderate doses of 3-MMC were well tolerated and safe and that potential health risks might only occur at high or excessive doses of 3-MMC.</div></div>","PeriodicalId":72899,"journal":{"name":"Emerging trends in drugs, addictions, and health","volume":"5 ","pages":"Article 100251"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145790087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sustained Use of Low-Dose Oral Ketamine as a Potential Antidepressant","authors":"G. Unal","doi":"10.1016/j.etdah.2025.100261","DOIUrl":"10.1016/j.etdah.2025.100261","url":null,"abstract":"<div><h3>Introduction</h3><div>Psychedelics have gained attention for their rapid-acting antidepressant properties, offering alternatives to the delayed onset and limited efficacy of traditional monoaminergic antidepressants. Ketamine, a non-competitive NMDA receptor antagonist and dissociative psychedelic, shows promise in this context. However, its clinical use has been largely restricted to intravenous racemic ketamine or intranasal esketamine.</div></div><div><h3>Methods</h3><div>We investigated the effects of long-term, low-dose oral ketamine administration (∼0.3 mg/day, ad libitum) and repeated oral gavage (15, 30, or 45 mg/kg for 3 doses) in adult male Wistar rats. Animals were tested in various behavioral paradigms relevant to depression.</div></div><div><h3>Results</h3><div>Voluntary consumption of low-dose oral ketamine produced antidepressant-like effects in the forced swim test, without impairing locomotion or working memory. Additionally, it prevented anhedonia in the sucrose preference test. The highest gavage dose (45 mg/kg) replicated these antidepressant effects.</div></div><div><h3>Conclusions</h3><div>These findings suggest that the antidepressant effects of ketamine or its enantiomers are not limited to high-dose, acute intravenous administration but can also be achieved through sustained, low-dose oral delivery—highlighting a promising and more accessible therapeutic route.</div></div>","PeriodicalId":72899,"journal":{"name":"Emerging trends in drugs, addictions, and health","volume":"5 ","pages":"Article 100261"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145790094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Frontiers in Psychedelic Research: A Scientometric Review of the Evolving Literature","authors":"R. Cavallaro,&nbsp;A. Carollo,&nbsp;O. Corazza,&nbsp;G. Esposito","doi":"10.1016/j.etdah.2025.100206","DOIUrl":"10.1016/j.etdah.2025.100206","url":null,"abstract":"<div><h3>Introduction</h3><div>Psychedelics have long been used in spiritual and medicinal contexts. Recently, growing scientific interest, driven by preliminary evidence of clinical efficacy, has renewed focus on their therapeutic potential. This study explores the historical evolution of clinical psychedelic research using a scientometric approach.</div></div><div><h3>Methods</h3><div>We downloaded 1664 documents from Scopus, covering the period from 1964 to 2025. Subsequently, we performed a document co-citation analysis on their 113,612 cited references to identify influential publications and thematic domains.</div></div><div><h3>Results</h3><div>Co-citation analysis revealed 81 key publications and ten thematic clusters, addressing topics such as the therapeutic use of LSD, the application of ketamine for treatment-resistant depression, the neurophysiological effects of psychedelics, and their implication in the treatment of depression, anxiety, and substance use disorders. The role of psychedelics also emerged within emerging therapeutic approaches, such as psychedelic-assisted psychotherapy, combining psychotherapeutic techniques with controlled administration of psychedelics. The analysis further highlighted recent key methodological, legislative, and ethical challenges associated with clinical implementation.</div></div><div><h3>Conclusions</h3><div>This study highlights the main thematic domains of research in the scientific literature on the clinical use of psychedelics. Findings suggest a strong focus on incorporating psychedelics in treating anxiety, depression, and substance use disorder, alongside persistent ethical concerns.</div></div>","PeriodicalId":72899,"journal":{"name":"Emerging trends in drugs, addictions, and health","volume":"5 ","pages":"Article 100206"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145790183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}